Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

References on ovarian and fallopian tube cancer

  1. Baekelandt M, Nesbakken AJ, Kristensen GB, Tropé CG, Abeler VA. Carcinoma of the fallopian tube. Clinicopathologic study of 151 patients treated at The Norwegian Radium Hospital. Cancer 2000; 89: 2076-84.
  2. Alvarado-Cabrero I, Young R, Vamvakas E, Scully RE. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999; 72: 367-79.
  3. Tamimi H, Figge D. Adenocarcinoma of the uterine tube: potential for lymph node metastasis. Am J Obstet Gynecol 1981; 141: 132-7.
  4. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006 Feb;30(2):230-6
  5. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT et al. Carcinoma of the Ovary. Int J Gynaecol Obstet 2006 Nov;95(1):161-192. 
  6. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT et al. Carcinoma of the fallopian tube. Int J Gynaecol Obstet 2006 Nov;95(1):145-160.
  7. Berek J, Friedlander M, Hacker N. Epithelial, fallopian tubae and peritoneal cancer. In: Berek and Hacker's gynecologic oncology. Berek JS, Hacker NF (eds.). ISBN: 978-0-7817-9512-8. Philadelphia PA: Lippincott Williams & Wilkins, 5th ed. 2010: 443-509
  8. Tropé C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, Onsrud M, Pettersen E, Rosenberg P, Sandvei R, Sundfør K, Vergote I. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000 Mar;11(3):281-8
  9. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Tropé C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J-A, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Baron B, Pecorelli S. Randomized Intergroup Trial of Cisplatin – Paclitaxel Versus Cisplatin – Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results. J Natl Cancer Inst 2000 May 3;92(9):699-708
  10. Tropé C, Kristensen G, Makar A. Surgery for Borderline Tumor of the Ovary. Semin Surg Oncol 2000 Jul-Aug;19(1):69-75.
  11. Tropé C, Marth C, Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 2000 Sep;36 Suppl 4:S59-61
  12. Tropé C, Scheistrøen M, Makar AP. Fertilitetsbevarende behandling ved gynekologisk kreft. [Fertility preservation in gynecologic cancer] Tidsskr Nor Laegeforen 2001 Apr 20;121(10):1234-9.
  13. Vergote I, DeBrabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore M.E, Kærn J, Verreist H, Sjövall K, Timmerman D, Vandewalle J, van Gramberen M, Tropé C. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Comments to article p159-160. Lancet 2001 Jan 20;357(9251):176-82
  14. The International Collaborative Ovarian Neoplasm (ICON) Group* Representing Norway: Baekelandt M, Jul Hansen L, Kaern J, Kristensen G, Onsrud M, Tropé C, Scheistroen M, The Norwegian Radium Hospital, Oslo and Hagen B, Lorenz E, University Hospital, Trondheim. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. The Lancet 2002;360:505-15
  15. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Tropé C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Adersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8
  16. Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Tropé C. Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer. Gynecol Oncol 2006 Sep;102(3):447-52
  17. Oksefjell H, Sandstad B, Tropé C. Ovarian cancer stage IIIC. consequences of treatment level on overall and progression-free survival. Eur J Gynaecol Oncol 2006;27(3):209-14
  18. Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009 Feb;20(2):286-93
  19. Tropé C, Davidson B, Paulsen T, Abeler VM, Kærn J. Diagnosis and treatment of borderline ovarian neoplasms ”the state of the art”. Eur J Gynaecol Oncol 2009;30(5):471-82.
  20. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53.
  21. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM; MRC OV05; EORTC 55955 investigators.Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010 Oct 2;376(9747):1155-63.
  22. Cancer in Norway 2013, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway.

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2016